NAC dosage regimen and different conditions refer from guidelines and micromedex
Reading File
Finding Sources
Finding Sources
Searching the Web
N-acetylcysteine NAC dosage regimen different conditions guidelines Micromedex 2024 2025
Reading File
Reading File
Reading Web Page
https://www.hhs.texas.gov/sites/default/files/documents/acet…
Reading File
Finding Sources
Searching the Web
NAC acetylcysteine dosage contrast nephropathy COPD mucolytic IPF renal guidelines Micromedex
I now have comprehensive data from multiple authoritative sources. Let me compile the full response:
N-Acetylcysteine (NAC) - Dosage Regimens by Condition
Sources: Harriet Lane Handbook 23e, Katzung's Pharmacology 16e, Murray & Nadel Respiratory Medicine, Goodman & Gilman, Essentials of Forensic Medicine & Toxicology 36e (2026), Micromedex Database (via Texas HHS Monograph), FDA Prescribing Information
Mechanism of Action (Brief)
NAC acts as a glutathione precursor (replenishes hepatic glutathione), direct free-radical scavenger, and mucolytic (breaks disulfide bonds in mucoproteins). Its antioxidant and anti-inflammatory properties underlie most off-label uses.
1. Acetaminophen (Paracetamol) Overdose - PRIMARY INDICATION
Most beneficial when given within 8-10 hours of overdose. Guided by the Rumack-Matthew nomogram.
Oral NAC (72-hour protocol - FDA approved)
| Dose | Amount | Timing |
|---|---|---|
| Loading dose | 140 mg/kg (max 15 g) | Single dose |
| Maintenance doses | 70 mg/kg (max 7.5 g) | Every 4 hours x 17 doses |
- Dilute to a 5% solution before administration
- Repeat dose if vomiting occurs within 1 hour of administration
- Continue until transaminases and INR have peaked and are substantially declining toward normal
Intravenous NAC (21-hour protocol - 3-bag method, FDA approved)
| Bag | Dose | Volume/Diluent | Infusion Time |
|---|---|---|---|
| Bag 1 (Loading) | 150 mg/kg (max 15 g) | 200 mL D5W (41 kg+) | 1 hour |
| Bag 2 (Second) | 50 mg/kg (max 5 g) | 500 mL D5W | 4 hours |
| Bag 3 (Third) | 100 mg/kg (max 10 g) | 1,000 mL D5W | 16 hours |
| Total | 300 mg/kg | 21 hours |
Pediatric weight-based dilution (5-20 kg): 3 mL/kg / 7 mL/kg / 14 mL/kg of diluent for bags 1/2/3 respectively.
Liver Failure Extension:
Continue the 100 mg/kg over 16-hour infusion (Bag 3 rate) until:
- Resolution of encephalopathy
- AST < 1,000 units/L
- INR < 2
Source: Harriet Lane Handbook 23e; FDA Prescribing Information (Acetylcysteine Injection); Essentials of Forensic Medicine & Toxicology 36e
2. Mucolytic - Respiratory Secretions
Inhalation (nebulization):
- 3-5 mL of 20% solution OR 6-10 mL of 10% solution via nebulizer
- Administered 3-4 times daily
- Can be given with bronchodilator pre-treatment to prevent bronchospasm
Oral (mucolytic for chronic bronchitis/COPD):
- 600 mg/day (standard dose) - most common regimen studied
- 1,200 mg/day (high dose) - used in exacerbation-prone patients
Note: Current GOLD guidelines and Goodman & Gilman do not recommend NAC routinely for COPD management, though it may reduce exacerbations in patients not on inhaled corticosteroids. Murray & Nadel reports mixed long-term data.
3. COPD - Prevention of Exacerbations (Off-label)
| Dose | Regimen | Evidence |
|---|---|---|
| 600 mg orally daily | Standard dose | 3-year RCT (BRONCUS): improved functional residual capacity; no significant change in FEV1 decline |
| 1,200 mg/day (600 mg BID) | High dose | Better exacerbation reduction, especially in patients NOT on inhaled steroids |
A recent meta-analysis (2021-2025 data) showed NAC at 600-1,200 mg/day for ≥6 months reduced exacerbation incidence by ~19% and improved cough, sputum, and dyspnea.
4. Contrast-Induced Nephropathy (CIN) Prevention (Off-label)
Standard oral protocol:
- 600 mg orally twice daily (1,200 mg/day)
- Start the day before the procedure (2 doses), continue the day of the procedure (2 doses)
- Total: 4 doses x 600 mg = 2,400 mg
- Given alongside IV hydration (0.9% NaCl 1 mL/kg/hr for 24 hrs)
High-dose oral protocol (higher-risk patients):
- 1,200 mg orally twice daily (start 24 hrs before contrast)
IV protocol (coronary angioplasty per AAFP/clinical protocols):
- 1,200 mg IV bolus before the procedure
- Then 1,200 mg orally twice daily x 48 hours post-procedure
Note: Evidence is mixed - the PRESERVE trial and some meta-analyses showed benefit, others did not. Most cardiology societies do not strongly endorse routine use, but it remains common given its safety profile.
5. Idiopathic Pulmonary Fibrosis (IPF) (Off-label)
- 1,800 mg/day in divided doses (600 mg three times daily)
- Used as adjunct to slow lung function deterioration
- The PANTHER-IPF trial showed that adding NAC to prednisone + azathioprine was harmful (increased mortality); NAC monotherapy showed no significant benefit over placebo
Source: Murray & Nadel; Fishman's Pulmonary Diseases. Not currently recommended in ATS/ERS/JRS/ALAT IPF guidelines.
6. Cystic Fibrosis
- Inhalation: 3-5 mL of 20% solution via nebulizer, 3-4 times/day (mucolytic)
- Oral: used off-label, doses variable (600-1,800 mg/day)
- Largely replaced by dornase alfa (DNase) for airway clearance in CF
7. Psychiatric Conditions (Off-label, via Micromedex)
| Condition | Dose | Notes |
|---|---|---|
| Obsessive-Compulsive Disorder (OCD) | Start 600 mg/day, double weekly to max 2,400 mg/day | Micromedex-documented off-label dose; benefits as adjunctive therapy ≥2,000 mg/day |
| Trichotillomania (TTM) | 1,200-2,400 mg/day | 12-week DBRCT showed benefit (Kaplan & Sadock) |
| Bipolar Disorder (depression phase) | 1,000-2,000 mg/day | Conflicting evidence; MADRS improvement shown in some studies |
| Substance Use Disorders / Addiction | 1,200-2,400 mg/day | Reduces cravings; evidence for cocaine, cannabis, nicotine |
| PTSD (adjunct to CBT) | 1,200 mg twice daily (2,400 mg/day) x 8 weeks | 81% reduction in cravings vs 32% placebo in one small study |
| Autism Spectrum Disorder | 900-2,700 mg/day (children) | Pilot RCT: 25% reduction in irritability scores |
Source: Texas HHS NAC Monograph (Micromedex Database); Kaplan & Sadock's Comprehensive Textbook of Psychiatry
8. Polycystic Ovary Syndrome (PCOS) (Off-label)
- 1,200 mg/day orally in divided doses
- Used as adjunct to clomiphene to improve ovulation induction
- Insulin-sensitizing and antioxidant effects proposed mechanism
9. Influenza Attenuation (Off-label)
- 600 mg orally twice daily (1,200 mg/day)
- Started before influenza season and continued throughout
- One double-blind RCT showed reduction in influenza symptoms and severity
10. Bronchiectasis (Off-label)
- 600 mg twice daily (per some guidelines for patients with copious secretions)
- International guidelines (ERS, BTS) mention use when excessive bronchial secretions are present; scientific evidence remains limited
Special Populations (Micromedex)
| Population | Guidance |
|---|---|
| Renal Impairment | No dosage adjustment required (Micromedex) |
| Hepatic Impairment | No specific adjustment; use cautiously |
| Geriatric | No specific dosage adjustment per manufacturer labeling |
| Pediatric | "Likely safe" at 900-2,700 mg/day for 8-12 weeks (Natural Medicines Database) |
| Pregnancy | "Likely safe" - crosses placenta but no fetal adverse effects; restrict to indicated use (acetaminophen toxicity) |
| Lactation | Avoid - insufficient data |
Key Safety Considerations
- Anaphylactoid reactions with IV NAC: most common during the loading dose (18% with 15-min infusion vs 14% with 60-min infusion); slow infusion rate reduces risk
- Bleeding: NAC has antiplatelet properties - use caution in bleeding disorders; discontinue 2 weeks before elective surgery
- Drug interactions: Potentiates vasodilatory effects of nitroglycerin - use caution
- Lab interference: False-positive serum chloride and urine ketone tests
- Look-alike/sound-alike: Do not confuse with L-cysteine (the amino acid)
- Oral formulation odor: Sulfurous smell may impair compliance; dilute in juice
Quick Reference Summary Table
| Condition | Route | Dose | Duration |
|---|---|---|---|
| APAP overdose (oral) | PO | 140 mg/kg load → 70 mg/kg q4h x17 | 72 hrs |
| APAP overdose (IV) | IV | 150→50→100 mg/kg (3-bag) | 21 hrs |
| Mucolytic (nebulized) | Inhaled | 3-5 mL of 20% TID-QID | As needed |
| COPD exacerbation prevention | PO | 600-1,200 mg/day | Long-term |
| Contrast nephropathy | PO | 600 mg BID x 2 days | Perioperative |
| IPF | PO | 1,800 mg/day | Off-label |
| OCD | PO | 600 mg → titrate to 2,400 mg/day | Off-label |
| PCOS (adj. clomiphene) | PO | 1,200 mg/day | Off-label |
| Influenza prevention | PO | 600 mg BID | Seasonal |
| TTM / Psychiatric | PO | 1,200-2,400 mg/day | Off-label |
This is a shared conversation. Sign in to Orris to start your own chat.